Indication for use: "The Svelte DES is indicated for improving coronary luminal diameter in patients with symptomatic heart disease, including patients with non-ST elevation MI due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length with a reference vessel diameter of 2.25 mm - 4.00 mm
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
1,630
PCI with implantation of a DES
Target Lesion Failure (TLF)
Time frame: 12 months
Target Vessel Failure (TVF)
Time frame: 6 and 12 months, and annually through 5 years
Major Adverse Cardiac Event (MACE)
Time frame: 6 and 12 months and annually through 5 years follow-up
Stent Thrombosis
Time frame: 6 and 12 months and annually through 5 years follow-up
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Thomas Hospital
Fairhope, Alabama, United States
Scottsdale Healthcare
Scottsdale, Arizona, United States
Arkansas Heart Hospital
Little Rock, Arkansas, United States
Bakersfield Memorial Hospital
Bakersfield, California, United States
Mission Cardiovascular Research Institute (Washington Hospital)
Fremont, California, United States
Long Beach VA Medical Center
Long Beach, California, United States
Keck Hospital of USC
Los Angeles, California, United States
San Francisco VA
San Francisco, California, United States
Christiana Hospital
Newark, Delaware, United States
Morton Plant Hospital
Clearwater, Florida, United States
...and 62 more locations